44P - The identification of circulating micro-RNAs (miRNA) to monitor tumour burden (tb) in small cell lung cancer (SCLC)

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Small-Cell Lung Cancer
Translational Research
Presenter Alastair Greystoke
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors A. Greystoke1, M. Ayub2, N. Smith1, C. Hodgkinson1, D. Morris1, R. Metcalf1, L. Carter1, F. Blackhall3, C. Dive1, G. Brady1
  • 1Clinical And Experimental Pharmacology, CRUK Manchester Institute, M20 4BX - Manchester/UK
  • 2Clinical And Experimental Pharmacology, CRUK Manchester Institute, Manchester/UK
  • 3Medical Oncology, Christie NHS Trust, Manchester/UK


SCLC is characterized by high metastatic burden, poor prognosis and emergence of treatment resistance. Sensitive circulating biomarkers of TB have potential to inform on progression prior to onset of symptoms, to aid in identifying novel treatment targets and as pharmacodynamic biomarkers in early clinical trials. We evaluated miRNA profiling of plasma from SCLC patients in order to identify potential biomarkers of TB. Using explants derived from patient circulating tumour cells (CTCs) we evaluated the relationship between levels of identified miRNA in the circulation and TB.